Neuroendocrine differentiation in prostatic carcinoma.

Area of Science:

• Urologic Oncology
• Cancer Biology
• Immunohistochemistry

Background:

• Neuroendocrine differentiation (NED) is a feature observed in various cancers, influencing tumor behavior and treatment response.
• The prevalence and characteristics of NED in prostatic adenocarcinoma require further elucidation.

Purpose of the Study:

• To investigate the incidence and patterns of neuroendocrine differentiation in prostatic carcinoma specimens.
• To characterize the neuroendocrine markers and hormone expression in positive cases.

Main Methods:

• Analysis of 53 prostatic carcinoma specimens using immunocytochemical tests for serotonin, neuron-specific enolase, and chromogranin.
• Application of the Churukian-Schenk argyrophil reaction.
• Further characterization with antisera to 12 polypeptide hormones and electron microscopy in select cases.

Main Results:

• Neuroendocrine differentiation was detected in 47% (25/53) of prostatic carcinomas, often with combined marker positivity.
• NED patterns included numerous cells (9%), focal scattered cells (11%), and rare cells (26%).
• Immunoreactivity for bombesin and calcitonin was observed in a small subset of cases; electron microscopy confirmed NED ultrastructurally.

Conclusions:

• Neuroendocrine differentiation is a relatively common finding in prostatic adenocarcinoma, spanning the histological spectrum.
• The identified NED does not typically resemble carcinoid or small cell carcinoma histologically.
• These findings contribute to understanding the molecular and cellular diversity within prostate cancer.